Skip to main content

Bio-Rad Says PCR Products Boost Q3 Life Science Sales


Bio-Rad Laboratories this week reported a 2 percent increase in its third-quarter revenues, to $471.5 million from $461.1 million in the comparable period of 2009.

Sales for the company's life science segment increased 2 percent to $153.2 million, while clinical diagnostics sales were also up around 2 percent to $314.9 million. Clinical diagnostic sales include $13.6 million from the Biotest business, which Bio-Rad acquired in the first quarter of 2010.

The company said in a statement that the life science segment "benefited from strong sales of core product lines," including its next-generation CFX96 real-time PCR detection system and associated reagents.

Bio-Rad posted net income of $44.8 million, or $1.59 per share, versus net income of $38.5 million, or $1.38 per share, for the prior-year period.

Third-quarter R&D spending increased around 9 percent to $42.9 million from $39.5 million, while SG&A expenses fell 3 percent to $148.7 million from $153.6 million.

Bio-Rad finished the quarter with $630.6 million in cash and cash equivalents and $107.4 million in short-term investments.

The firm expects organic revenue growth for full-year 2010 to be in the 4 percent to 5 percent range. The company expects to report fourth-quarter sales of between $510 million and $520 million.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.